Cantor Fitzgerald Predicts Innoviva FY2025 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Innoviva in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will earn $1.55 per share for the year. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The firm had revenue of $89.51 million during the quarter.

Separately, StockNews.com downgraded Innoviva from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st.

Innoviva Trading Up 0.9 %

Shares of INVA stock opened at $18.75 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 27.17 and a beta of 0.54. Innoviva has a 52-week low of $14.32 and a 52-week high of $21.28. The company has a 50-day simple moving average of $18.37 and a two-hundred day simple moving average of $18.77.

Institutional Investors Weigh In On Innoviva

Several large investors have recently made changes to their positions in the business. Barclays PLC grew its position in Innoviva by 254.2% during the third quarter. Barclays PLC now owns 100,594 shares of the biotechnology company’s stock valued at $1,942,000 after buying an additional 72,192 shares during the period. Jane Street Group LLC boosted its stake in Innoviva by 46.4% in the third quarter. Jane Street Group LLC now owns 136,361 shares of the biotechnology company’s stock valued at $2,633,000 after acquiring an additional 43,218 shares during the last quarter. FMR LLC grew its position in shares of Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 771 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in shares of Innoviva during the 3rd quarter worth approximately $715,000. Finally, Victory Capital Management Inc. raised its holdings in shares of Innoviva by 3.5% in the 3rd quarter. Victory Capital Management Inc. now owns 140,454 shares of the biotechnology company’s stock worth $2,712,000 after purchasing an additional 4,699 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.